References
- European Glaucoma SocietyTerminology and Guidelines for Glaucoma4th edSavona, ItalyEditrice Dogma2014
- HeijlALeskeMCBengtssonBHymanLBengtssonBHusseinMReduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma TrialArch Ophthalmol2002120101268127912365904
- ChauhanBCMikelbergFSArtesPHCanadian Glaucoma Study: 3. Impact of risk factors and intraocular pressure reduction on the rates of visual field changeArch Ophthalmol2010128101249125520696979
- QuigleyHABromanATThe number of people with glaucoma worldwide in 2010 and 2020Br J Ophthalmol200690326226716488940
- McKeeHDRGuptaMSAhadMASaldanaMInnesJRFirst-choice treatment preferences for primary open-angle glaucoma in the United KingdomEye200519892392415375365
- AptelFCucheratMDenisPEfficacy and tolerability of prostaglandin analogs: a meta-analysis of randomized controlled clinical trialsJ Glaucoma200817866767319092464
- LinLZhaoYJChewPTComparative efficacy and tolerability of topical prostaglandin analogues for primary open-angle glaucoma and ocular hypertensionAnn Pharmacother201448121585159325184309
- KatzLJCohenJSBatoosinghALFelixCShuVSchiffmanRMTwelve-month, randomized, controlled trial of bimatoprost 0.01%, 0.0125%, and 0.03% in patients with glaucoma or ocular hypertensionAm J Ophthalmol2010149466167120346780
- MyersJSVoldSZamanFWilliamsJMHollanderDABimatoprost 0.01% or 0.03% in patients with glaucoma or ocular hypertension previously treated with latanoprost: two randomized 12-week trialsClin Ophthalmol2014864365224707169
- Allergan LtdLumigan® 0.1 mg/ml Summary of Product CharacteristicsElectronic Medicines Compendium (eMC)2014 Available from http://www.medicines.org.uk/EMC/medicine/22807/SPC/Lumigan+0.1mg+ml/Accessed February 20, 2015
- CrichtonACNixonDRSimonyiSAn observational study of bimatoprost 0.01% in patients on prior intraocular pressure-lowering therapy: the Canadian Lumigan RC Early Analysis Review (CLEAR) trialClin Ophthalmol201481031103824920879
- FigusMNardiMPiaggiPBimatoprost 0.01% vs bimatoprost 0.03%: a 12-month prospective trial of clinical and in vivo confocal microscopy in glaucoma patientsEye201428442242924434659
- NixonDRSimonyiSBhogalMAn observational study of bimatoprost 0.01% in treatment-naive patients with primary open angle glaucoma or ocular hypertension: the CLEAR trialClin Ophthalmol201262097210323269858
- PfennigsdorfSRamezOvon KistowskiGMulticenter, prospective, open-label, observational study of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertensionClin Ophthalmol2012673974622654501
- CampbellJHSchwartzGLaBountyBKowalskiJPatelVDComparison of adherence and persistence with bimatoprost 0.01% versus bimatoprost 0.03% topical ophthalmic solutionsCurr Med Res Opin20132991201120923865686
- McCarneyRWarnerJIliffeSvan HaselenRGriffinMFisherPThe Hawthorn Effect: a randomised, controlled trialBMC Med Res Methodol20077303817608932